Altimmune IncALT
Price$2.86

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $41K+105.0% YoYTTM through 30 Jun 2026
Net Income -$91.8MTTM through 30 Jun 2026
Free Cash Flow -$76.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
Operating Margin-244,451.2%
Net Margin-223,804.9%

Returns

-32.1%ROE
-27.1%ROA

Balance Sheet Health

Debt / Equity0.12x
Current Ratio29.29x
Net Debt-$297Mnet cash position
Cash & Equivalents$63M

Quality Metrics

Altman Z-Score5.77
Piotroski F-Score4 / 9
FCF Margin-186,736.6%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'10'11'21'22'23'24'25
FY2025: $41K
Diluted EPS-$0.76TTM
'16'20'21'22'23'24'25
FY2025: $-1.00

Dividend

No dividend

Capital Allocation

Capex Intensity131.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.